Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chugai Pharmaceutical
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18 and ≤65 years of age at the time of consent.
Patients with Atopic Dermatitis
Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit
Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit
static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit
You may not be if
Serological evidence of hepatitis B virus or hepatitis C virus infection
Known human immunodeficiency virus infection
Ongoing treatment with specific or non-specific hyposensitization therapy for AD
Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week prior to randomization
History of infection including skin infection requiring treatment with oral or intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to randomization.
Evidence of tuberculosis (TB) infection as defined by a positive purified protein derivative (PPD) and/or positive interferon-gamma release assay.